Company: SMNR
Filing Date: 2025-04-21
Form Type: S-4/A
Source: 0001193125-25-087342
Chunk: 229

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-21
Form: S-4/A
Chunk 229
---
 |     | announcements of the introduction of new products by New Semnur’s competitors; |

| • |     | market conditions and trends in the pharmaceutical and biotechnology sectors; |

| • |     | announcements concerning product development results or intellectual property rights of others; |

| • |     | future issuances of common stock or other securities; |

| • |     | the recruitment or departure of key personnel; |

| • |     | failure to meet or exceed any financial guidance or expectations regarding product development milestones that New Semnur may provide to the public; |

| • |     | actual or anticipated variations in quarterly operating results; |

| • |     | New Semnur’s failure to meet or exceed the estimates and projections of the investment community; |

| • |     | overall performance of the equity markets and other factors that may be unrelated to New Semnur’s operating performance or the operating performance of its competitors, including changes in market valuations of similar companies; |

| • |     | announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by New Semnur or its competitors; |

| • |     | changes in financial estimates by New Semnur or by any securities analysts who might cover its stock; |

| • |     | fluctuation of the market values of any of New Semnur’s potential strategic investments; |

| • |     | issuances of debt or equity securities; |

| • |     | compliance with New Semnur’s contractual obligations; |

128

| • |     | sales of New Semnur Common Stock by New Semnur or its stockholders in the future; |

| • |     | trading volume of New Semnur Common Stock; |

| • |     | ineffectiveness of New Semnur’s internal controls; |

| • |     | publication of research reports about New Semnur or its industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; |

| • |     | New Semnur’s relationship with Scilex; |

| • |     | general political and economic conditions, including the wars in Ukraine and Israel; |

| • |     | effects of natural or man-made catastrophic events; |

| • |     | effects of public health crises, pandemics and epidemics; and |

| • |     | other events or factors, many of which are beyond New Semnur’s control, such as the government closure of Silicon Valley Bank and Signature Bank, and liquidity